In recent days, the office of the national leadership group for the identification and management of high technology enterprises has published the public notices for filing the first high technology enterprises identified by the liaoning prefectural identification agency in 2025, and the northeast pharmaceutical group corporation, inc., has been re-elected to the public notice list with the preparation of a declaration of deep technological accumulation, strong innovative dynamics and norms. This outcome represents a combination of corporate strengths in areas such as core technology r & d and the transformation of scientific and technological results, with sustained national-level authority。
It is known that high-technology enterprises have a three-year cycle, with stringent requirements on the number of autonomous intellectual property rights (iprs) of the core technology of enterprises, the development of scientific research, and the ability to transform scientific and technological results. The new declaration of northeast pharmaceuticals was coordinated by the company's technological department, which set up a special working group to systematize the core declaration elements of the r & d system, the autonomous intellectual property reserve and the conversion of scientific and technological results. In close collaboration and efficiency, the departments concerned are working to ensure the orderly development of the declaration process, in strict compliance with the national identification criteria, through the integration of materials and the improvement of multiple rounds of internal verification and optimization。
As the national centre for enterprise technology, north-east pharmaceuticals has consistently pursued innovative-driven development strategies, and in recent years has been investing more in research and development, with the cost of research and development increasing by 95 per cent in the first three quarters of the year and making major breakthroughs in front-line areas such as oncological immunization. Currently, the company has accumulated a multi-tumour target cell treatment product, of which the self-developed dcty0801 injection (for the treatment of re-emergence or progress of egrviii positives) has been clinically tested and the product is eligible for united states fda orphan medicine. Through sustained intensive farming in the area of innovation, companies have built a double-wheel-drive product matrix of “innovation + generics” that provides a solid foundation for high-quality enterprise development。
This reaffirmation of the qualifications of high-technology enterprises at the national level will not only provide a high level of recognition of the innovative capacity and level of research and development of companies, but will also provide an important platform for companies to follow up on tax incentives, gain policy support and expand high-end market cooperation to further enhance their core competitiveness and industry influence。
It is worth mentioning that there are currently five high-technology enterprises under the northeast pharmaceutical corporation, namely, the northeast pharmaceutical group shenyang first pharmaceutical company ltd., the northeast pharmaceutical group liaoning biomedicine company ltd., shen yang dong swe fine chemical industry co. Ltd., the toung pharma group shen yang shie pharmaceutical industry ltd., and beijing penang zhengen biotechnology co. Ltd., which have created a good pattern of clustering of innovative power at the group level. The endorsement of high-technology enterprise qualifications as an authority for enterprise r & d and innovation capabilities has an important positive impact on accelerating the technological transformation of enterprises, enhancing brand image and enhancing market value。
In the future, northeast pharmaceuticals will take advantage of this re-election as an opportunity to further increase investment in research and development resources, to further develop the core technical areas of medicine, to accelerate the process of industrialization of scientific and technological results, to promote product upgrades and industrial structure optimization, to continuously improve core competitiveness and to contribute more northeast pharmaceutical power to the quality development of the enabling pharmaceutical industry。
